Vertex (VRTX) Q2 2026 earnings review
Growth Accelerates on Non-CF Ramp and $8.8B Endocrine Expansion
Vertex delivered a strong second quarter, with total revenue growth accelerating to 12% YoY ($3.33B), breaking a pattern of decelerating growth seen in prior quarters. The primary catalyst is the long-awaited acceleration in non-CF products: both CASGEVY and JOURNAVX jumped over 70% sequentially. The core Cystic Fibrosis franchise remains highly resilient, executing a swift transition from TRIKAFTA to ALYFTREK. Management raised the lower end of full-year revenue guidance to $13.1B. Furthermore, the company announced an $8.8B cash acquisition of Crinetics, deploying its pristine balance sheet to add a fifth growth pillar in rare endocrine diseases.
🐂 Bull Case
The non-CF portfolio is accelerating rapidly. CASGEVY (+78% QoQ) and JOURNAVX (+71% QoQ) are firmly on track to hit management's FY26 target of >$500M in non-CF revenue, proving Vertex can execute beyond Cystic Fibrosis.
The $8.8B acquisition of Crinetics seamlessly bolts on a new late-stage rare endocrine disease pipeline without straining the balance sheet, ensuring growth well into the 2030s.
🐻 Bear Case
Operating leverage is deteriorating. While revenue grew 12%, Non-GAAP SG&A skyrocketed 45% YoY to $520M as the company funds the massive JOURNAVX and upcoming renal commercial build-outs.
Despite a massive 535,000 prescriptions filled in the quarter, JOURNAVX generated only $49.6M in revenue, implying a net realization of less than $100 per script due to heavy patient support discounting.
⚖️ Verdict: 🟢
Bullish. Vertex is successfully pulling off one of the hardest maneuvers in biotech: pivoting from a single-franchise monopoly to a diversified powerhouse. While SG&A is heavy, the top-line acceleration and Crinetics acquisition justify the spend.
Key Themes
ALYFTREK Cannibalization Executing Perfectly
The transition within the core CF franchise is stable and going exactly as planned. TRIKAFTA revenues declined slightly to $2.5B, but this was entirely offset by the accelerating adoption of ALYFTREK, which surged to $573.6M. This internal cannibalization improves patient outcomes and Vertex's long-term royalty economics.
Crinetics Acquisition Mints a Fifth Pillar
Vertex is acquiring Crinetics for $8.8B net cash, establishing rare endocrinology as its fifth growth pillar. This diversifies the company away from pulmonary and renal dependency and utilizes the massive $13.6B cash pile that was sitting on the balance sheet.
Gene-Editing Commercialization Validated
CASGEVY, utilizing CRISPR/Cas9 ex vivo gene-editing technology, achieved $76.4M in Q2 (+78% QoQ). Furthermore, the FDA's rapid 53-day approval for children ages 2+ opens the market to ~5,500 new eligible patients. The long cycle times from cell collection to infusion are finally converting into recognized revenue.
The Glaring Contradiction: JOURNAVX Rx Volume vs. Revenue
There is a massive disconnect between JOURNAVX adoption and monetization. The company touted 535,000 prescriptions filled in Q2 (accelerating from Q1), yet recognized only $49.6M in revenue. This contradiction highlights that gross-to-net normalization has not yet occurred, and Vertex is heavily subsidizing the launch through patient support programs.
SG&A Spending Spikes While R&D Stagnates
Vertex is paying a steep price for its diversification. Non-GAAP SG&A accelerated drastically to $520.2M (+45% YoY) to support the JOURNAVX sales force and the upcoming renal launch. Conversely, Non-GAAP R&D remained essentially flat at $888.7M. This dynamic will compress operating margins until the new launches achieve scale.
Renal Franchise Approaching the Starting Line
Povetacicept is marching toward its November 30 PDUFA date for IgA Nephropathy. If approved, it validates Vertex's dual BAFF/APRIL inhibitor mechanism. Management is already spending heavily on a specialized nephrology sales force to ensure a rapid commercial ramp upon approval.
The CF Innovation Ceiling
While overall CF revenue grew 11%, the runway for future step-change innovation is shrinking. Management has previously noted there is 'very little unmet need' remaining with ALYFTREK. Consequently, the bar for the next-generation VX-828 (Phase 3 data expected H2 2026) is extraordinarily high, and demonstrating clinical superiority may prove difficult.
Macroeconomic Trade Exposures Flagged
In its guidance reaffirmation, management explicitly noted that their 2026 projections include an 'immaterial cost impact from tariffs.' While currently modeled as immaterial, the specific call-out of 'currently known tariff rates' indicates a vulnerability to escalating global trade tensions, particularly as the company scales manufacturing for complex small molecules globally.
Other KPIs
Accelerating significantly from $12.3B at the end of FY25. This fortress balance sheet fully covers the upcoming $8.8B cash outlay required for the Crinetics acquisition without necessitating debt issuance or dilutive equity offerings.
Reversing. The tax rate rose compared to 19.4% in 25Q2. This higher rate is dragging down bottom-line growth, resulting in Non-GAAP net income growing only 3% YoY ($1.20B vs $1.16B) despite the robust 12% top-line revenue growth.
Guidance
Accelerating. Raised from the prior range of $12.95 - $13.1B. At the $13.15B midpoint, this implies an acceleration to 9.6% annual growth (up from 9% growth in FY25), driven by the steepening ramps of CASGEVY and JOURNAVX combined with CF resilience.
Stable. Unchanged from prior guidance. With H1 2026 Non-CF revenues tracking at ~$198 million, and both CASGEVY and JOURNAVX compounding at >70% quarter-over-quarter, this target appears highly achievable.
Stable. Maintained prior guidance despite the massive Q2 SG&A print. However, this does *not* include the impact of the Crinetics acquisition. Investors should expect a material upward revision to OpEx guidance following the anticipated Q3 close.
Key Questions
JOURNAVX Gross-to-Net Normalization
With 535,000 prescriptions generating only $50M in revenue, the per-script realization remains heavily suppressed. What specific milestones in Medicare Part D or commercial contracting must be hit in H2 2026 to see revenue track closer to prescription volume?
Crinetics Integration and OpEx Impact
Current OpEx guidance excludes Crinetics. Once the $8.8B acquisition closes in Q3, what level of incremental R&D and SG&A burn should investors model for the remainder of 2026 and heading into 2027?
Povetacicept Commercial Strategy
With the PDUFA date for IgAN set for November 30, how much of the 45% YoY surge in SG&A is directly attributable to the renal sales force build-out, and are you fully staffed for a Day 1 launch?
VX-828 Value Proposition
Given ALYFTREK's success in returning 65% of children to carrier sweat chloride levels, what specific magnitude of clinical improvement must the next-generation VX-828 demonstrate to justify a transition, and is the FDA aligned on that endpoint?